EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction

David Tryon, Michel T Corban, Mohamad Alkhouli, Abhiram Prasad, Claire E Raphael, Charanjit S Rihal, Guy S Reeder, Brad Lewis, Diana Albers, Rajiv Gulati, Amir Lerman

JACC: Cardiovascular Interventions · 2024

DOI: 10.1016/j.jcin.2024.09.018 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von David Tryon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Quality of Life, Microcirculation, Coronary Sinus, Angina Pectoris. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Coronary microvascular dysfunction (CMD) is a common cause of angina with no obstructive coronary artery disease (ANOCA), and effective treatment options are limited. OBJECTIVES: This study aims to assess the safety and efficacy of the coronary sinus (CS) Reducer (Neovasc, Inc/Shockwave Medical) for treatment of angina in patients with CMD. METHODS: This Phase II trial enrolled 30 patients with ANOCA, invasively diagnosed CMD, and Canadian Cardiovascular Society (CCS) class 3 to 4 angina despite medical therapy. CMD was defined by coronary flow reserve (CFR) ≤2.5 and/or ≤50% increase in coronary blood flow (CBF) in response to intracoronary infusion of acetylcholine. Invasive coronary microvascular function testing was performed before and at 120 days postimplantation. The primary endpoint was change in microvascular function at 120 days. Secondary endpoints were changes in CCS angina class and Seattle Angina Questionnaire (SAQ) scores. RESULTS: Mean age was 54.8 ± 11.0 years; 67% (20/30) were women. In patients with low baseline CFR (endothelium-independent CMD), CFR increased significantly from 2.1 (1.95-2.30) to 2.7 (2.45-2.95) (n = 19; P = 0.0011). Patients with abnormal CBF response to acetylcholine at baseline (endothelium-dependent CMD) had an increase in CBF response to acetylcholine: -11.0% (-20.15% to 5.85%) to 11.5% (-4.82% to 39.29%) (n = 11; P = 0.042). There was a significant improvement in CCS angina class from 4.0 (3.25-4.0) to 2.0 (2.0-3.0) (P < 0.001) and increase in each domain of the SAQ questionnaire (P < 0.006 for all). CONCLUSIONS: This study demonstrates that the CS Reducer is associated with significant improvement in angina, quality of life, and coronary microvascular function in patients with CMD and may emerge as a novel therapy for patients with ANOCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeMicrocirculationCoronary SinusAngina PectorisHumansFemaleMaleMiddle AgedTreatment OutcomeAgedTime FactorsSurveys and QuestionnairesVasodilator AgentsAdultAcetylcholineCoronary CirculationCardiovascular AgentsRecovery of FunctionProspective StudiesCoronary Vessels

Stichwörter der Autor:innen

ANOCAangina with no obstructive coronary artery diseasecoronary microvascular dysfunctioncoronary sinus reducermicrovascular angina

Substanzen

Vasodilator AgentsAcetylcholineCardiovascular Agents

Autor:innen und Institutionen

  • Mayo Clinic, Rochester, Minnesota, USA.
  • Mayo Clinic, Rochester, Minnesota, USA; Sarver Heart Center, University of Arizona College of Medicine Tucson, Arizona, USA.
  • Mayo Clinic, Rochester, Minnesota, USA. Electronic address: lerman.amir@mayo.edu.

Zitieren

APA

Tryon, D., Corban, M. T., Alkhouli, M., Prasad, A., Raphael, C. E., Rihal, C. S., Reeder, G. S., Lewis, B., Albers, D., Gulati, R., & Lerman, A. (2024). Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.09.018

Vancouver

Tryon D, Corban MT, Alkhouli M, Prasad A, Raphael CE, Rihal CS, et al. Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.09.018

BibTeX
@article{Tryon2024,
  author = {Tryon, David and Corban, Michel T and Alkhouli, Mohamad and Prasad, Abhiram and Raphael, Claire E and Rihal, Charanjit S and Reeder, Guy S and Lewis, Brad and Albers, Diana and Gulati, Rajiv and Lerman, Amir},
  title = {Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  doi = {10.1016/j.jcin.2024.09.018}
}
Kostenlos starten →